OKYO Pharma Ltd — Director's Dealing 2022

May 16, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OKYO Pharma Ltd (OKYO)
CIK: 0001849296
Period of Report: 2022-05-16

Reporting Person: Shah Keeren (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$0.2025	2028-08-19	Ordinary Shares (300000)		Direct
Option (right to buy)	$0.0640	2031-08-31	Ordinary Shares (500000)		Direct
Option (right to buy)	$0.1045	2032-01-31	Ordinary Shares (150000)		Direct

Footnotes

F1: 25% will vest each year on August 1, beginning on August 2, 2020.

F2: 25% will vest each year on August 1, beginning on August 31, 2021.

F3: Vest in equal amounts over three years beginning on January 31, 2022.